Clinical trials: Rectal Cancer, Radiotherapy
Rectal Cancer, Radiotherapy
IMRT Versus 3DCRT for Locally Advanced Rectal Cancer, Prospective Phase II Study.
The goal of this prospective phase II study was to determine whether personalized planning-based nCRT for LARC would indeed decrease small bowel dose, and whether selected plans, specifically prioritizing lower dose to small…
- Conditions
- Rectal Cancer, Radiotherapy, Toxicity Due to Radiotherapy
- Trial name
- NCT06160570
- Testing
- Intensive Modulated Radiation Therapy, 3-Dimension Conformal Radiation Therapy
- Where
- Israel
- Volunteers
- 75 people
- Sponsor
- Rabin Medical Center
Metastatic Colorectal Cancer, Radiotherapy
Consolidative Radiotherapy Plus Maintenance Chemotherapy for Metastatic Colorectal Cancer
This study is a randomized phase II trial of maintenance chemotherapy versus consolidative radiotherapy plus maintenance chemotherapy for patients with unresectable metastatic colorectal cancer (MCRC).
- Trial name
- MCRC-LC1 (NCT03142282)
- Testing
- maintenance chemotherapy, Consolidative Radiotherapy
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Mismatch Repair-proficient, Colorectal Cancer Metastatic
Radiotherapy Combined With Tislelizumab and Irinotecan in MSS/pMMR Recurrence and Metastatic Colorectal Cancer
Explore the efficacy of radiotherapy combined with Tislelizumab and irinotecan in MSS/pMMR inoperable recurrent and metastatic colorectal cancer patients; To evaluate the safety and tolerability of radiotherapy combined with…
- Conditions
- Mismatch Repair-proficient, Colorectal Cancer Metastatic, Microsatellite Stable
- Trial name
- NCT05160727
- Testing
- Tislelizumab, Irinotecan, radiotherapy
- Where
- China
- Volunteers
- 44 people
- Sponsor
- Zhejiang Cancer Hospital
Colorectal Cancer, Liver Metastases
COLDFIRE-III Trial: Efficacy of Irreversible Electroporation and Stereotactic Body Radiotherapy for Perivascular and Peribiliary Colorectal Liver Metastases
The primary objective of this phase IIb/III, prospective, randomized clinical trial is to compare the efficacy of irreversible electroporation (IRE) with stereotactic body radiotherapy (SBRT) in patients with perivascular or…
- Conditions
- Colorectal Cancer, Liver Metastases, Liver Metastasis Colon Cancer, Unresectable Solid Tumor
- Trial name
- COLDFIRE-III (NCT06185556)
- Testing
- Irreversible electroporation, Stereotactic body radiotherapy
- Where
- Netherlands
- Volunteers
- 78 people
- Sponsor
- Amsterdam UMC, location VUmc
Prostate Cancer
Hyaluronic Acid for Hypofractionated Prostate Radiotherapy
The present Phase II study aims to assess the rates of late rectal toxicities of grade ≥ 2 after hypofractionated radiotherapy of prostate cancer of 62 Gy in 20 fractions of 3.1 Gy with an injection of hyaluronic acid (HA) in the…
- Trial name
- RPAH1 (NCT02165020)
- Testing
- Hyaluronic acid (Macrolane VRF 30®, Q-MED)
- Where
- France
- Volunteers
- 36 people
- Sponsor
- Hospices Civils de Lyon
Colorectal Cancer, Liver Metastases
SBRT + PD-1 Monoclonal Antibody in Unresectable Colorectal Liver Metastases
To explore the efficacy and safety of stereotactic body radiation therapy (SBRT) combined with PD-1 monoclonal antibody in the treatment of unresectable colorectal cancer liver metastasis through a prospective study, providing…
- Trial name
- SPARKLE-L (NCT06794086)
- Testing
- Stereotactic body radiation therapy, PD-1 Monoclonal Antibody, Chemotherapy
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Jun Huang
Locally Advanced Rectal Adenocarcinoma
Simultaneous Boost in Neoadjuvant Radiotherapy for Rectal Cancer
The goal of this clinical trial is to learn whether new adjuvant radiotherapy with gross tumor volume(GTV) escalated to 58.75 Gy can improve complete response (CR) rates compared with GTV dose of 50 Gy in adult patients (18-79…
- Trial name
- SIB-NCRT (NCT07200141)
- Testing
- GTV 58.75 Gy/25 fractions(Simultaneous Integrated Boost), GTV 50 Gy/25 fractions(Simultaneous Integrated Boost), Concurrent Chemotherapy
- Where
- China
- Volunteers
- 156 people
- Sponsor
- Peking Union Medical College Hospital
Chronic Radiation-induced Proctitis
KANGFUPEN Liquid Dressing for Chronic Radiation-Induced Rectal Injury
This clinical trial aims to evaluate the efficacy and safety of Kangfupen (a topical liquid dressing) in treating chronic radiation-induced proctitis (RTOG Grade 2 or higher). The key questions we aim to answer are: 1.
- Trial name
- NCT07065175
- Testing
- Kangfupen (liquid dressing) retention enema administration
- Where
- China
- Volunteers
- 65 people
- Sponsor
- Peking Union Medical College Hospital
Microsatellite Instability High, Mismatch Repair Deficiency
Anti-PD-1 +/- RT for MSI-H Solid Tumors
To determine if the out-of-field ORR is improved with the addition of radiation therapy to anti-PD-1 for patients with MSI-H/dMMR metastatic solid tumors.
- Conditions
- Microsatellite Instability High, Mismatch Repair Deficiency, Colorectal Cancer
- Trial name
- NCT04001101
- Testing
- RT and Anti-PD-1, Anti-PD-1
- Where
- United States
- Sponsor
- University of Colorado, Denver
Rectal Neoplasm Malignant
Total Mesorectal Excision(TME) With Lateral Lymph Node Dissection Versus TME After Neoadjuvant Chemo-radiotherapy
Treatment for Low rectal cancer, especially in patients with regional lymph node metastasis are quite different between Japanese guideline (JSCCR) and western countries' guideline (NCCN, ESMO).
- Trial name
- TELEPHOME (NCT03587480)
- Testing
- TME+LLND, TME+nCRT
- Where
- China
- Volunteers
- 250 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Recurrent Rectal Cancer
Phase I/II Trial Evaluating Carbon Ion Radiotherapy for the Treatment of Recurrent Rectal Cancer
Treatment standard for patients with rectal cancer depends on the initial staging and includes surgical resection, radiotherapy as well as chemotherapy.
- Trial name
- PANDORA (NCT01528683)
- Testing
- Carbon Ion Radiotherapy
- Where
- Germany
- Volunteers
- 14 people
- Sponsor
- University Hospital Heidelberg
Colorectal Cancer
S0713: Oxaliplatin, Capecitabine, Cetuximab, and RT Followed By Surgery in Pts W/Stage II or III Rectal Cancer
RATIONALE: Drugs used in chemotherapy, such as oxaliplatin and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00686166
- Testing
- cetuximab, capecitabine, oxaliplatin
- Where
- 130 sites in United States
- Volunteers
- 83 people
- Sponsor
- SWOG Cancer Research Network
Locally Advanced Rectal Cancer
Short-course Radiotherapy Based TNT Combined With PD-1 Inhibitor for Locally Advanced Rectal Cancer
TORCH is a prospective, multicentre, randomized phase II trial. 130 LARC (T3-4/N+M0, distance from anal verge ≤12cm) patients will be treated with total neoadjuvant therapy (TNT) and assigned to Group A and Group B.
- Trial name
- TORCH (NCT04518280)
- Testing
- PD-1 antibody, Capecitabine, Oxaliplatin
- Where
- 3 sites in China
- Volunteers
- 130 people
- Sponsor
- Fudan University
Metastatic Cancer Rectum
The Role of Short Course of Palliative Radiation in Metastatic Cancer Rectum
Short-course radiotherapy (SCRT), which allows the delivery of 25 Gy in five daily fractions, has emerged as an attractive strategy for rectal cancer treatment.
- Trial name
- NCT06521827
- Testing
- short course radiotherapy
- Volunteers
- 49 people
- Sponsor
- Assiut University
Rectal Cancer
Capecitabine + Irinotecan Followed by Combined Modality Capecitabine and Radiation in Locally Advanced Rectal Cancer
Preoperative induction chemotherapy has been successfully used in a variety of malignancies and provides several advantages over postoperative therapy.
- Trial name
- NCT00216086
- Testing
- Capecitabine, Irinotecan, EUS
- Where
- 9 sites in United States
- Volunteers
- 22 people
- Sponsor
- Gabi Chiorean, MD
Anal Cancer
Shortening Radiation Course Duration Using Simultaneous Integrated Boost With Lower Intensity Elective Nodal Dosing and Concurrent Chemotherapy for High-Risk Anal Squamous Cell Carcinoma
This phase 2 single-arm study will evaluate whether a shortened course of mildly hypofractionated radiation therapy given with standard concurrent chemotherapy (mitomycin C and capecitabine) can provide acceptable tumor control…
- Trial name
- SSIBLING (NCT07775209)
- Testing
- Hypofractionated Radiation Therapy
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Vermont Medical Center
Prostate Cancer
Stereotactic Ablative Radiotherapy (SABR) for Low Risk Prostate Cancer With Injectable Rectal Spacer
The purpose is to determine if use of rectal spacers are effective at improving protection of rectum from high dose radiation, using rate of rectal ulceration as a surrogate measure of acute effects.
- Trial name
- NCT02353832
- Testing
- Injectable Rectal Spacer (SpaceOAR, Duraseal or equivalent)
- Where
- 2 sites in United States
- Volunteers
- 44 people
- Sponsor
- University of Texas Southwestern Medical Center
Rectal Adenocarcinoma
Role of Neoadjuvent Radiotherapy in Locally Advanced Cancer Rectum
This is a retrospective study comparing neoadjuvent short course radiotherapy to conventional chemoradiation in locally advanced cancer rectum and the effect of both regimens in overall survival and disease free survival
- Trial name
- NCT04814784
- Testing
- Neoadjuvent radiotherapy either short or long course chemoradiation in treatment of locally advanced cancer rectum
- Where
- Egypt
- Volunteers
- 48 people
- Sponsor
- Amany sayed Abass
Rectal Tumors, Rectal Cancer
Organ-sparing With TraceIT® for Rectal Cancer Radiotherapy
For advanced rectal tumors, the standard of care is neoadjuvant radiotherapy (RT) +/- chemotherapy followed by surgery 8-10 weeks later.
- Conditions
- Rectal Tumors, Rectal Cancer, Advanced Cancer
- Trial name
- NCT03258541
- Testing
- TraceIT®, Volumetric Arc Therapy (VMAT), Surgery
- Where
- Switzerland
- Volunteers
- 2 people
- Sponsor
- Thomas Zilli
Rectal Cancer, Comorbidities and Coexisting Conditions
Watch and Wait Management on Rectal Cancer Patients Using New Swift Local Therapy
Within our institution, the principal investigator have acquired expertise in endorectal brachytherapy, a localized treatment for colorectal cancer.
- Conditions
- Rectal Cancer, Comorbidities and Coexisting Conditions, Inoperable Disease, Brachytherapy
- Trial name
- Whistle (NCT04336202)
- Testing
- External beam radiotherapy + Endorectal brachytherapy
- Where
- Canada
- Volunteers
- 45 people
- Sponsor
- Sir Mortimer B. Davis - Jewish General Hospital